•
AR
ARQT
Arcutis Biotherapeutics, Inc. Common Stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
3.27B
Volume
11.76K
52W High
$31.77
52W Low
$11.13
Open
$26.69
Prev Close
$26.70
Day Range
26.60 - 26.69
About Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Latest News
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
GlobeNewswire Inc.•Yesterday
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares
The Motley Fool•Dec 23
This Biotech Stock Could Cure Your Portfolio's Pain
The Motley Fool•Dec 14
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
GlobeNewswire Inc.•Dec 8
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
GlobeNewswire Inc.•Nov 17
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Nov 7
Arcutis to Present at Upcoming Investor Conferences
GlobeNewswire Inc.•Oct 27
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Oct 3